What is API Holdings Limited?

API Holdings Limited is the parent holding company of PharmEasy, India's largest digital pharmacy and healthcare platform. Incorporated in 2019, it holds operating subsidiaries including Ascent Health and Wellness Solutions (PharmEasy retail pharmacy aggregator) and a significant stake in Thyrocare Technologies Limited (diagnostics).

Who are the founders of PharmEasy?

PharmEasy was founded by Siddharth Shah, Dhaval Shah, Dharmil Sheth, Harsh Parekh, and Hardik Dedhia. Siddharth Shah serves as CEO of API Holdings.

What happened to PharmEasy's valuation?

At its peak in 2021, API Holdings was valued at USD 5.6 billion, making it one of India's most valuable health-tech unicorns. A rights issue in FY2023 implied a valuation of approximately USD 300–400 million — a roughly 90% decline from peak — amid heavy losses and a challenging funding environment.

Is API Holdings listed?

No. API Holdings Limited is an unlisted public company. Its subsidiary Thyrocare Technologies Limited is separately listed on NSE and BSE (ticker: THYROCARE).

What is PharmEasy's business model?

PharmEasy operates as a marketplace aggregating pharmacies, enabling customers to order prescription and OTC medicines for home delivery. It also offers diagnostic test booking (via Thyrocare), teleconsultation, and chronic disease management programs. Revenue comes from commissions on medicine orders, diagnostic bookings, and subscription health plans.

How do I buy API Holdings (PharmEasy) unlisted shares here?

Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.

Who am I actually transacting with?

You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.

How do I pay, and is there a payment gateway?

Payment is by direct bank transfer to Prospire Network Private Limited's published account (CIN U82300UP2025PTC233622), shown to you in-app at the payment step. There is no card gateway and no escrow. Never pay to a personal account or to any account shared over phone, WhatsApp or email — even if the person claims to be from our team.

How long does settlement take?

After you accept an allocation, you have a short window to pay (typically 2 days). Once payment is verified, shares are usually credited to your demat within 2–3 business days, subject to depository timelines and any company-level restrictions. Timeframes are typical, not guaranteed.

There are no separate platform fee lines and no GST on the transfer — the desk's margin is built into the buy/sell price you're quoted. The only statutory add-on on a purchase is stamp duty on the consideration, shown transparently in your cost breakdown.

Is there a minimum ticket size for API Holdings (PharmEasy)?

Minimums vary by company and depend on the lot the desk can source. Raise an enquiry and the desk will confirm the available quantity and the minimum for that name.

What KYC do I need, and do I need a demat account?

You'll share your demat details when you enquire so we can settle directly. Full KYC — PAN and a client-master / demat statement — is required before the transfer step, when shares actually change hands. Yes, you need an active demat account to hold unlisted shares.

Are there lock-ins on unlisted or pre-IPO shares?

Some shares carry statutory or company-imposed lock-ins — for example, a post-listing lock-in on pre-IPO stock — and transfers can be subject to the company's articles or approvals. Where a lock-in applies, we'll flag it before you commit.

How do I sell API Holdings (PharmEasy) shares I already hold?

Raise a sell enquiry with the company, quantity and your target price. The desk confirms a buying price, you transfer your shares into the desk's demat, and once the credit is verified we pay you out by bank transfer to your registered account. The desk never pays out before your shares are received.

Unlisted shares are illiquid, may be hard or impossible to sell, and are not covered by exchange settlement guarantees or investor-protection funds. Pricing is indicative, not live. Read the full Risk Disclosure before you enquire, and invest only what you can afford to lock away.

API Holdings (PharmEasy) Unlisted Share Price | Buy API Holdings (PharmEasy) Pre-IPO Shares — wisefolio

Investment Thesis

API Holdings (PharmEasy) represents a high-risk, high-uncertainty investment in India's digital health space. While it holds a strategically valuable position as the leading online pharmacy aggregator and controls the listed Thyrocare diagnostics business, its financial distress and dramatic valuation collapse from peak make this a speculative bet. The current price of INR 5.7 per share reflects the deep uncertainty around its ability to achieve profitability without further dilution. Only investors with a very high risk appetite and long-term horizon should consider exposure.

Pros

Largest online pharmacy and digital health platform in India by GMV, operating under the PharmEasy brand
Full-stack healthcare platform integrating diagnostics (Thyrocare acquisition), teleconsultation, and medication delivery
Strong network of 60,000+ pharmacy stores onboarded on the platform
Thyrocare Technologies stake provides a listed-subsidiary anchor with a stable diagnostic revenue stream
Significant data moat from prescription and diagnostic records enabling personalised health services

Cons

Severe financial distress: down-round fundraising at ~90% valuation cut from peak USD 5.6 billion (2021) to ~USD 300–400 million range
Persistent and large net losses; cash burn has required multiple emergency funding tranches
Rights issue in 2023 at a deep discount diluted existing shareholders significantly
Regulatory headwinds: uncertainty around online pharmacy licensing norms in India
Intense competition from Tata 1mg, Apollo Pharmacy Online, Flipkart Health+, and Amazon Pharmacy
Thyrocare stake partially pledged/sold during financial stress, reducing strategic flexibility

Business Segments

Online Pharmacy (PharmEasy)

Aggregates 60,000+ pharmacy partners; customers order prescription and OTC medicines via app/website for home delivery. Largest segment by GMV.

Diagnostics (Thyrocare)

Thyrocare Technologies Limited (listed subsidiary) provides diagnostic testing services across India with a hub-and-spoke lab network. API Holdings holds a majority stake.

Teleconsultation & Digital Health

Connects patients with doctors online for consultations; integrated with chronic disease management and medication delivery workflows.

Revenue Model

API Holdings generates revenue through commissions from pharmacy partners on medicine orders placed via the PharmEasy platform, revenue consolidation from majority-owned Thyrocare Technologies (diagnostic services), subscription fees for chronic disease management plans, and fees from teleconsultation services. A B2B arm also supplies medicines to hospital pharmacies.

Detailed Analysis

Growth outlookExpansion plans, industry tailwinds & headwinds12

Growth Plans

Regulatory clarity on online pharmacies enabling a more scalable and compliant operating model

Thyrocare growth driving consolidated profitability improvement

Potential re-filing of IPO once financial metrics improve

Market consolidation in digital pharmacy with weaker players exiting

Industry Tailwinds

Recent Developments

Down-round rights issue

API Holdings raised funds through a rights issue at an implied valuation of approximately USD 300–400 million, representing a ~90% cut from its 2021 peak of USD 5.6 billion. This significantly diluted existing shareholders and highlighted the depth of its financial challenges.

2023

Thyrocare stake monetisation

API Holdings explored options for its Thyrocare stake (including partial stake sales) to improve liquidity and reduce debt at the holding company level.

2024

Operational restructuring

PharmEasy undertook workforce rationalisation, reduced warehouse footprint, and narrowed geographic focus to high-margin markets in an effort to reduce cash burn and demonstrate a viable path to profitability.

2024

Comparable Companies

CompanyTypeTickerMkt Cap

Tata 1mg (Tata Health)ListedUnlisted (subsidiary of Tata Digital)~USD 1.5 billion (last implied valuation)

Thyrocare Technologies LimitedListedTHYROCARE (NSE/BSE)~INR 4,000–5,000 crore (2024)

Apollo Hospitals Enterprise LimitedListedAPOLLOHOSP (NSE/BSE)~INR 90,000 crore (2024)

Tata 1mg (Tata Health)Listed

Unlisted (subsidiary of Tata Digital) · ~USD 1.5 billion (last implied valuation)

Frequently Asked Questions

About API Holdings (PharmEasy)

API Holdings Limited is the parent holding company of PharmEasy — India's largest digital health and online pharmacy platform. Incorporated in 2019 in Mumbai, API Holdings consolidates the PharmEasy group's operations spanning online pharmacy, diagnostics, teleconsultation, and pharmaceutical supply chain services. PharmEasy was founded in 2015 by Dharmil Bodani and Dhaval Shah with the vision of making healthcare accessible and affordable across India. The platform enables consumers to order prescription and OTC medicines, book diagnostic tests, and consult doctors online. PharmEasy has grown to become one of India's most significant healthcare technology companies, with operations in 1,000+ cities and over 100 million registered users. In 2021, PharmEasy made a transformational acquisition of Thyrocare Technologies (listed diagnostic company) for approximately Rs 4,546 crore, becoming one of India's first healthtech unicorns to acquire a publicly listed company. The company raised $1.5 billion in funding at a peak valuation of approximately $5.6 billion, attracting investors including Prosus/Naspers, TPG, Temasek, and B Capital. However, API Holdings' IPO journey has been troubled. The company filed a DRHP with SEBI in late 2021 for a Rs 6,250 crore IPO but subsequently withdrew the filing in 2022 amid market corrections and concerns about losses. The company was forced to raise emergency funding in 2022-23 at significantly lower valuations as it faced cash burn and revenue growth challenges. In 2023, PharmEasy sold its Thyrocare stake to reduce debt. As of 2025, the company continues to operate its pharmacy aggregation platform while working towards profitability.

Key Milestones

2015 — PharmEasy founded by five co-founders as an online pharmacy aggregator

Common questions about unlisted shares

How do I buy API Holdings (PharmEasy) unlisted shares here?
Raise an enquiry on any company with the quantity you want. Our desk sources the shares and comes back with a firm price and allocation. You accept the allocation, transfer the funds to the desk's published bank account, and once we verify payment the shares are transferred into your demat.
Who am I actually transacting with?
You transact with the desk, not with an anonymous counterparty. When you buy, you buy from the desk; when you sell, you sell to the desk. Shares always route through the desk's own demat account, so there's one accountable party for the whole trade.
How do I pay, and is there a payment gateway?

API Holdings Limited

How settlement works

Get price alerts for API Holdings Limited

Discuss API Holdings (PharmEasy)

Other ways to invest